Literature DB >> 2619357

Clearance of inhaled particles in ankylosing spondylitis.

D R Farquhar1, M J Chamberlain, G A McCain, W K Morgan.   

Abstract

Patients with ankylosing spondylitis may uncommonly develop apical fibrobullous lung disease, the cause of which is unknown. It is postulated here that rigidity of the thoracic cage leads to reduced apical clearance of inhaled particles and may thereby predispose to chronic infection. Deposition and clearance of inhaled technetium-99m sulphur colloid particles were studied in eight male patients with ankylosing spondylitis who had chest wall rigidity (mean (SD) chest expansion 1.8 (1.07) cm) but normal chest radiographs. As a reference population eight healthy male volunteers were also studied. Particle deposition showed an increasing gradient from apex to base, with no significant difference between patients and controls. Clearance was assessed by comparing absolute counts, corrected for decay, at 24 hours with the baseline values. No delay in particle clearance in those with ankylosing spondylitis was apparent.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2619357      PMCID: PMC1003933          DOI: 10.1136/ard.48.12.974

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  4 in total

1.  The lung in ankylosing spondylitis.

Authors:  G Gacad; P Hamosh
Journal:  Am Rev Respir Dis       Date:  1973-02

2.  Regional lung function in ankylosing spondylitis.

Authors:  R M Stewart; J B Ridyard; J D Pearson
Journal:  Thorax       Date:  1976-08       Impact factor: 9.139

3.  Factors influencing the regional deposition of inhaled particles in man.

Authors:  M J Chamberlain; W K Morgan; S Vinitski
Journal:  Clin Sci (Lond)       Date:  1983-01       Impact factor: 6.124

4.  Regional lung ventilation in ankylosing spondylitis.

Authors:  A Parkin; P J Robinson; P Hickling
Journal:  Br J Radiol       Date:  1982-11       Impact factor: 3.039

  4 in total
  1 in total

1.  Pulmonary involvement in ankylosing spondylitis.

Authors:  Percival D Sampaio-Barros; Elza Maria F P Cerqueira; Sílvio M Rezende; Lucimara Maeda; Roseneide A Conde; Verônica A Zanardi; Manoel Barros Bértolo; José Ribeiro de Menezes Neto; Adil M Samara
Journal:  Clin Rheumatol       Date:  2006-03-30       Impact factor: 2.980

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.